Four startups from the medical field obtain the Innosuisse Certificate

After completing the Innosuisse Core Coaching program, startups can apply for the Innosuisse Certificate, to boost their track record. Upon receiving their applications, the Innosuisse Innovation Council evaluates the entries based on the startup’s innovativeness, financial readiness for external funding, and management structure, followed by the awarding of the certificate to startups deemed ready for further growth.

The recent recipients in the medical field are:

Hi-D Imaging – founded in 2019 as an ETH spin-off, the startup is developing the world’s first AI-based pre-operational planning tool, which enables physicians to perform personalized planning ahead of cardiac surgery for the treatment of structural heart diseases. The solution aims to address current limitations of medical scans for patients with cardiovascular diseases and reduce unnecessary medical imaging examinations. Alongside the founders, Utku Gulan and Özge Karaka is a team of five employees pushing the company to the next level.

Testmate Health – developed a low-cost, over-the-counter diagnostic urine test for STIs, with the initial focus on chlamydia and gonorrhea. The easy-to-use test delivers results within 30 minutes, hence eliminating the need for medical visits while granting privacy and convenience. As the company gears up to launch the test, it has garnered the attention of investors who contributed $6M in its seed funding round.

Perivision – with its primary goal is to help prevent blindness caused by glaucoma, which affects approximately 80 million people worldwide, the startup developed the VisionOne Platform, a virtual reality (VR) visual field test with industry-leading speed and accuracy for diagnosing and monitoring glaucoma. Its AI algorithms are used to optimize the tests, automate assistance, control quality, and provide valuable insights for clinical decisions. The combination of these technologies put the company on track to revolutionize eye care. The company has validated the solution in clinical studies, raised funding as it prepares to enter the US and European market.

Adiposs – developed a medical imaging product called ImageBAT, which is a first-in-class CT contrast agent for visualizing and quantifying activated brown adipose tissue (BAT). Non-invasive, pain-free, and compatible with all CT scanners available in hospitals worldwide, the product is designed to identify patients with increased risks of cancer progression, higher risk of treatment failure, and shorter survival. Founded in 2020 as a spin-off from the University of Geneva, the startup completed phase I clinical trials last year and plans to run a phase II clinical trial in patients with advanced lung cancer in Europe in 2024.

(RAN)